Richard Allan

1.0k total citations
39 papers, 661 citations indexed

About

Richard Allan is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, Richard Allan has authored 39 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 13 papers in Physiology and 5 papers in Immunology and Allergy. Recurrent topics in Richard Allan's work include Inhalation and Respiratory Drug Delivery (11 papers), Asthma and respiratory diseases (11 papers) and Allergic Rhinitis and Sensitization (5 papers). Richard Allan is often cited by papers focused on Inhalation and Respiratory Drug Delivery (11 papers), Asthma and respiratory diseases (11 papers) and Allergic Rhinitis and Sensitization (5 papers). Richard Allan collaborates with scholars based in United Kingdom, United States and Australia. Richard Allan's co-authors include T. R. Watson, Dominic Kwiatkowski, Ieuan Jones, María Cristina De Salvo, William MacNee, Michael S. Roberts, Peter Braithwaite, J. Alexandra Rowe, John A. Williams and Nolan Wood and has published in prestigious journals such as Gastroenterology, Gut and Journal of Allergy and Clinical Immunology.

In The Last Decade

Richard Allan

37 papers receiving 625 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Allan United Kingdom 14 127 109 105 92 80 39 661
Patricia S. Latham United States 18 94 0.7× 106 1.0× 375 3.6× 61 0.7× 157 2.0× 58 1.1k
Maria Imaculada Muniz‐Junqueira Brazil 19 78 0.6× 69 0.6× 163 1.6× 321 3.5× 158 2.0× 59 889
Renato Barboza Brazil 18 88 0.7× 52 0.5× 120 1.1× 160 1.7× 58 0.7× 28 595
Dovile Anderson Australia 15 174 1.4× 112 1.0× 345 3.3× 97 1.1× 49 0.6× 31 787
Evan O. Gregg United Kingdom 16 147 1.2× 46 0.4× 133 1.3× 51 0.6× 183 2.3× 28 666
Kenneth Hedlund Sweden 16 274 2.2× 63 0.6× 120 1.1× 32 0.3× 21 0.3× 38 943
Michael Bray Switzerland 13 135 1.1× 67 0.6× 156 1.5× 288 3.1× 340 4.3× 23 872
Dana B. Walker United States 16 42 0.3× 28 0.3× 115 1.1× 113 1.2× 40 0.5× 26 770
Alfredo Lagunas-Martínez Mexico 15 83 0.7× 33 0.3× 316 3.0× 44 0.5× 152 1.9× 52 608
Regina J. Brown United States 13 135 1.1× 28 0.3× 386 3.7× 90 1.0× 31 0.4× 18 717

Countries citing papers authored by Richard Allan

Since Specialization
Citations

This map shows the geographic impact of Richard Allan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Allan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Allan more than expected).

Fields of papers citing papers by Richard Allan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Allan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Allan. The network helps show where Richard Allan may publish in the future.

Co-authorship network of co-authors of Richard Allan

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Allan. A scholar is included among the top collaborators of Richard Allan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Allan. Richard Allan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cooper, Andrew, et al.. (2020). Wixela Inhub: Dosing Performance In Vitro and Inhaled Flow Rates in Healthy Subjects and Patients Compared with Advair Diskus. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 33(6). 323–341. 10 indexed citations
2.
Donohue, James F., et al.. (2020). Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD. Pulmonary Therapy. 7(1). 47–57. 2 indexed citations
3.
Allan, Richard, et al.. (2020). Usability and Robustness of the Wixela Inhub Dry Powder Inhaler. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 34(2). 134–145. 9 indexed citations
4.
Ng, Dik, Edward Kerwin, Martha V. White, et al.. (2019). Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 33(2). 99–107. 11 indexed citations
5.
6.
Haughie, Scott, et al.. (2019). Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 33(1). 34–42. 10 indexed citations
7.
Allan, Richard, et al.. (2019). Usability and Robustness of the Wixela® Inhub® Dry Powder Inhaler. A2206–A2206.
8.
Brown, Russell E., et al.. (2014). Just in Case EoL Drugs in Patients' Homes - Prescribing and Outcomes in a Cancer Network. Palliative Medicine. 28(6). 750–751. 1 indexed citations
9.
North, Michelle L., Lisa M. Steacy, Richard Allan, et al.. (2014). Add-on histamine receptor-3 antagonist for allergic rhinitis: a double blind randomized crossover trial using the environmental exposure unit. Allergy Asthma and Clinical Immunology. 10(1). 33–33. 17 indexed citations
10.
11.
Stokes, Jeffrey R., F.A. Romero, Richard Allan, et al.. (2011). The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. Journal of Allergy and Clinical Immunology. 129(2). 409–412.e2. 41 indexed citations
12.
Allan, Richard. (2009). Orale elementen in de Homerische grammatica: Intonatie-eenheid en enjambement. VU Research Portal. 42(2). 136–151. 3 indexed citations
13.
Abel, Sylvie, Richard Allan, Kuan Gandelman, et al.. (2008). Pharmacokinetics, Safety and Tolerance of Voriconazole in Renally??Impaired Subjects. Clinical Drug Investigation. 28(7). 409–420. 42 indexed citations
14.
Țuțuian, Radu, Inder Mainie, Richard Allan, et al.. (2006). Effects of a 5‐HT4 receptor agonist on oesophageal function and gastro‐oesophageal reflux: studies using combined impedance‐manometry and combined impedance‐pH. Alimentary Pharmacology & Therapeutics. 24(1). 155–162. 29 indexed citations
15.
Wood, Nolan, Keith Tan, Richard Allan, Anitra Fielding, & D. J. Nichols. (2001). Effect of voriconazole on the pharmacokinetics of omeprazole. 41. 2. 2 indexed citations
16.
Allan, Richard. (1997). Structural analogues of ZAPA as GABAA agonists. Neurochemistry International. 30(6). 583–591. 8 indexed citations
17.
Braithwaite, Peter, Michael S. Roberts, Richard Allan, & T. R. Watson. (1982). Clinical pharmacokinetics of high dose mebendazole in patients treated for cystic hydatid disease. European Journal of Clinical Pharmacology. 22(2). 161–169. 73 indexed citations
18.
Allan, Richard, et al.. (1977). Crohn's disease involving the colon: an audit of clinical management.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 73(4 Pt 1). 723–32. 39 indexed citations
19.
Allan, Richard, David M. Steinberg, K. E. Dixon, & W. T. Cooke. (1975). Changes in the bidirectional sodium flux across the intestinal mucosa in Crohn's disease.. Gut. 16(3). 201–204. 32 indexed citations
20.
Allan, Richard, et al.. (1975). An Incubation Flask to Study Metabolism of Foreign Compounds by Intestinal Microflora. Xenobiotica. 5(7). 407–411. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patricia S. Latham Breakdown of academic impact, for papers by Maria Imaculada Muniz‐Junqueira Breakdown of academic impact, for papers by Renato Barboza Breakdown of academic impact, for papers by Dovile Anderson Breakdown of academic impact, for papers by Evan O. Gregg Breakdown of academic impact, for papers by Kenneth Hedlund Breakdown of academic impact, for papers by Michael Bray Breakdown of academic impact, for papers by Dana B. Walker Breakdown of academic impact, for papers by Alfredo Lagunas-Martínez Breakdown of academic impact, for papers by Regina J. Brown
Rankless by CCL
2026